Design, synthesis, and biological evaluation of KA7, a novel quinolone-based
sorafenib analogue with potent anticancer and immunomodulatory activities
#MMPMID41384066
Abuarqoub D
; Alshaikh A
; Mohammad M
; Khalaf H
; Albaz N
; Hmedat A
RSC Adv
2025[Dec]; 15
(57
): 49353-49363
PMID41384066
show ga
Although multi-kinase inhibitors like sorafenib remain an important treatment
option for advanced malignancies, their toxicity and resistance to treatment are
problems. Enhancing its structure by making changes to the scaffold offers a
viable way to boost safety and effectiveness. In this study,
2-(4-chlorobenzylamino)-6-(pyridin-4-yloxy) quinolin-4(1H)-one (KA7), a novel
sorafenib analogue, is synthesized and biologically evaluated. KA7 was
synthesized by replacing the urea component of sorafenib with a quinolone
scaffold. Then, KA7 was characterized by NMR and HRMS. MTT tests were used to
calculate the IC(50) and assess cytotoxicity against breast (MDA-231, MCF-7),
glioblastoma (U87), and lung (A549) cancer cells. Flow cytometry was used to
evaluate cell death induction (apoptosis/necrosis), cell cycle analysis, and
autophagic activity. The analysis of cytokine release in LPS-stimulated THP-1
macrophages allowed for the determination of KA7's immunomodulatory potential.
Our results indicated that KA7 exhibited IC(50) values lower than those of
sorafenib in both U87 and A549 cells, with similar effects observed in MCF-7
cells, demonstrating dose-dependent cytotoxicity. Flow cytometry also revealed a
significant increase in apoptosis and G1 phase cell cycle arrest across all
cancer cell lines tested. Autophagy induced by KA7 was confirmed through acridine
orange staining. In the macrophage model, KA7 increased levels of
anti-inflammatory cytokines (IL-8 and IL-10) while decreasing pro-inflammatory
cytokines (IL-1?, TNF-?, and IL-6), supporting an immunomodulatory profile akin
to that of sorafenib. In conclusion, KA7 exhibits strong anticancer properties,
inducing apoptosis, arresting the G1 cell cycle, stimulating autophagy, and
displaying positive immunomodulatory effects. According to these results, KA7 is
a promising lead chemical for additional preclinical testing as a potent
sorafenib substitute.
free
free
free
